See where your brand stands in AI answers

Free. About a minute. No sign-up.

Know where you stand. Find your next opportunity.

What AI says about RGX-121 | Parse

Track RGX-121. Free.

RGX-121

What AI says about RGX-121

AI named RGX-121 in August 2026.

Question: What are the latest affordable advancements in biopharma for treating rare diseases?

ChatGPT SearchAug 25, 2026

For example, the FDA placed a clinical hold on Regenxbio's Hunter-syndrome gene therapy RGX-121 on August 24, 2026

Track RGX-121: see where AI mentions it and what to do next.

AI named RGX-121 alongside Avlayah, Genglycos, and Otarmeni.

AI leaned on fda.gov, reuters.com, and arpa-h.gov in the answers that named RGX-121.

What are the latest affordable advancements in biopharma for treating rare diseases?
Excerpts where RGX-121 appeared in the AI's answer
ChatGPT SearchAug 25, 2026, ChatGPT Search
For example, the FDA placed a clinical hold on Regenxbio's Hunter-syndrome gene therapy RGX-121 on August 24, 2026